Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

BLENREP 100 mg powder for concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
belantamab mafodotin
Company:  
GlaxoSmithKline UK See contact details
ATC code: 
L01FX15
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Live Chat HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Eye Care Evaluation guide for Physicians and Eye Care Professionals

{healthcare_pro_orange} For Healthcare Professionals

This guide provides instructions to facilitate communication between prescribers and eye care professionals for corneal monitoring and management of patients receiving treatment with belantamab mafodotin.

{pdf_link}

Important Information for Physicians: Management of Corneal Adverse Reactions

{healthcare_pro_orange} For Healthcare Professionals

This guide is to provide healthcare professionals with an overview of corneal adverse reactions that may occur with belantamab mafodotin treatment and guidance regarding supportive care and dose modifications to manage corneal adverse reactions

{pdf_link}

Important Information for Eye Care Professionals: Corneal Adverse Reactions

{healthcare_pro_orange} For Healthcare Professionals

This guide is to provide eye care professionals with an overview of corneal adverse reactions that may occur with belantamab mafodotin treatment and to explain the important role of eye care professionals in the monitoring and management of patients receiving belantamab mafodotin

{pdf_link}

Patient guide: Important information on Understanding the Vision and Eye Changes with treatment

{healthcare_pro_orange} For Healthcare Professionals

This guide for patients provides an overview of the vision and eye changes that may occur with belantamab mafodotin treatment.

{pdf_link}

Cover Letter – Risk Minimisation Materials

{healthcare_pro_orange} For Healthcare Professionals

This letter outlines the risk minimisation materials developed to explain the corneal adverse reactions that may occur with belantamab mafodotin treatment and to provide monitoring and management guidance.

{pdf_link}

Patient Wallet Card

This patient wallet card should be given to all patients to record their care team contact details. Patients should carry this card with them at all times.

{pdf_link}

Pharmacy Eye Drop wallet Card

This eye drop wallet card should be given to all patients to present to their pharmacist who will help provide preservative-free artificial tears eye drops. Patients should carry this card with them at all times

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

GlaxoSmithKline UK
Company image
Address
980 Great West Road, Brentford, Middlesex, TW8 9GS, UK
Telephone
0800 221 441
E-mail
[email protected]
Medical Information e-mail
[email protected]
Adverse event reporting email
[email protected]